GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Carmell Corp (NAS:CTCX) » Definitions » PS Ratio

Carmell (Carmell) PS Ratio : 52.56 (As of May. 17, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Carmell PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Carmell's share price is $2.05. Carmell's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.04. Hence, Carmell's PS Ratio for today is 52.56.

The historical rank and industry rank for Carmell's PS Ratio or its related term are showing as below:

CTCX' s PS Ratio Range Over the Past 10 Years
Min: 9.65   Med: 53.59   Max: 96.15
Current: 53.7

During the past 3 years, Carmell's highest PS Ratio was 96.15. The lowest was 9.65. And the median was 53.59.

CTCX's PS Ratio is ranked worse than
80.4% of 1000 companies
in the Biotechnology industry
Industry Median: 9.155 vs CTCX: 53.70

Carmell's Revenue per Sharefor the three months ended in Dec. 2023 was $-0.16. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.04.

Back to Basics: PS Ratio


Carmell PS Ratio Historical Data

The historical data trend for Carmell's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Carmell PS Ratio Chart

Carmell Annual Data
Trend Dec21 Dec22 Dec23
PS Ratio
- - -

Carmell Quarterly Data
Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial - - - 18.01 -

Competitive Comparison of Carmell's PS Ratio

For the Biotechnology subindustry, Carmell's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Carmell's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Carmell's PS Ratio distribution charts can be found below:

* The bar in red indicates where Carmell's PS Ratio falls into.



Carmell PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Carmell's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=2.05/0.039
=52.56

Carmell's Share Price of today is $2.05.
Carmell's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Carmell  (NAS:CTCX) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Carmell PS Ratio Related Terms

Thank you for viewing the detailed overview of Carmell's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Carmell (Carmell) Business Description

Traded in Other Exchanges
N/A
Address
2403 Sidney Street, Suite 300, Pittsburgh, PA, USA, 15203
Carmell Corp is a regenerative care company with a focus on using human biomaterials for aesthetic and medical care. Its commercial product is a human amnion allograft that can be used as a structural barrier for wound healing. Carmell's R&D pipeline includes several innovative aesthetic, epithelial and bone products under development.
Executives
David W Anderson director 519 LYNMERE ROAD, BRYN MAWR PA 19010
Kathryn Gregory director 305 THAYER POND ROAD, WILTON CT 06897
Patrick A Sturgeon officer: CFO and Secretary 600 LEXINGTON AVENUE 33 FLOOR, NEW YORK NY 10022
Richard A Upton director 12 MIDDLE STREET, AMHERST NH 03031
Rajiv Shukla director, 10 percent owner, officer: Chief Executive Officer EMERALD VIEW SUITE 400, 2054 VISTA PARKWAY, WEST PALM BEACH FL 33411
Randolph W Hubbell director, officer: President and CEO C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
William R Newlin director C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Steven Bariahtaris director C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Jaime Garza director C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Janet Vargo officer: VP Clinical Services C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Donna Godward officer: Chief Quality Officer C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
James C Hart officer: Chief Medical Officer C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
William Woodward director ANTHEM VENTURE PARTNERS, 225 ARIZONA AVENUE, SUITE 200, SANTA MONICA CA 90401
Darlene T Deremer director 200 CENTRAL AVENUE, SUITE 1850, ST. PETERSBURG FL 33701
Ahac Sponsor Iii Llc 10 percent owner 1177 AVENUE OF THE AMERICAS, 5TH FLOOR, NEW YORK NY 10036